Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
By D. Cardinale, A. Colombo, M. Sandri, Giuseppina Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, C. Cipolla. Circulation, 2006
932 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/6bcc1d9d9cf98116a8172650c6faf56d58cbdb1d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Oncology
Citations in the corpus
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “001 Breast cancer 131 (58) 1213 (51) Hodgkin’s disease 10 (4) 113 (5) Non-Hodgkin’s lymphoma 46 (20) 695 (29) Myeloma 8 (4) 144 (6) Ovarian 2 (1) 67 (3) Other hematoncologic diseases 10 (4) 76 (3) Other solid tumors 19 (8) 91 (4) Cumulative anthracycline dose, ‡§ mg/mq 359 172 299 144 <0.”
- Anthracycline Chemotherapy and Cardiotoxicity (2017, background): “because some cardioprotection studies suggest that anthracycline cardiotoxicity maybe reversible if detected within 3–6 months of a decline in ejection fraction [71, 72].”
- Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, result): “In cancer patients undergoing high-dose chemoherapy, enalapril was shown to prevent a decline in LVEF s well as cardiac events when compared with the control roup (58).”
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “Patients with anti-VEGF-based therapy with signs and symptoms of HF.”